Phase 2 clinical trials up to 26 weeks in insulin-naive or previously insulin-treated individuals with type 2 diabetes have shown low rates of level 2 and level 3 hypoglycaemia for once-weekly icodec that are comparable to once-daily glargine U100 [11–13]. This evidence concerns the gene INS and type 2 diabetes mellitus.